Navigation Links
Refractory Hematological Malignances Treatment Opportunities Discussed in MP Advisors Report Published at MarketPublishers.com
Date:9/12/2013

London, UK (PRWEB) September 12, 2013

Recently, cancer treatment has witnessed considerable breakthroughs in terms of the development of innovative drug products. The success in clinical research in this therapeutic area and growth in investments are attributed to positive clinical data and regulatory approvals, expanding partnerships and mergers and acquisitions (M&A) activity.

Some companies that have already scored a success in the development of novel technology platforms and drugs to treat relapsed and refractory multiple myeloma (RRMM), are expected to follow a similar scenario to unfold in the treatment of recurrent/refractory MDS (RR-MDS, High-Risk MDS) and AML (relapsed/ refractory AML, R/R AML).

Insightful research report “Treating Refractory Hematological Malignancies – Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics” worked out by MP Advisors has been recently published by Market Publishers Ltd.

Report Details:

Title: Treating Refractory Hematological Malignancies – Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics
Published: August, 2013
Pages: 37
Price:    US$ 2,500.00
http://marketpublishers.com/report/company_reports/treating-refractory-hematological-malignancies-v-myelodysplastic-syndromes-mds-n-acute-myeloid-leukemia-aml-emerging-therapeutics.html

The report offers an insightful overview of the approved therapies for MDS and AML, discusses the unmet needs as well as limitations of the current standard of care (SOC) for relapsed and refractory patients. The study examines commercial opportunities in purchasing the therapy area, evaluates the competitive pressure in the sphere; makes up a comprehensive list of drugs (both early-stage and late-stage) in the clinic, and also uncovers data on their mechanism of action and companies developing them; besides profiling the leading companies. The report presents a review of the recent mergers and acquisitions in the area; covers products available for in-licensing; discusses the major trends and issues related to the therapeutic area.

Report Scope:

  •     Insightful overview of the disease and a detailed discussion of the unmet needs.
  •     Vital information on the drugs in pipeline including mechanism of action (MoA) and clinical stage of development.
  •     Review of the key milestones.
  •     Data on the launch timeline and commercial opportunity of late-stage pipeline (RR MDS and RR AML).
  •     Extensive overview of the mergers and acquisitions and licensing deals over the past five years.
  •     Evaluation of the in-licensing and/or mergers and acquisitions opportunity.
  •     Description of the competitive scenario and detailed profiles of companies, including their clinical drug data, milestones and valuation.

More insightful research reports by MP Advisors can be found at http://marketpublishers.com/members/mpadvisors/info.html.

About Us:

MarketPublishers.com is a multilingual hypermarket offering a rich collection of comprehensive studies on various markets, sectors, industries, companies, etc. We perform professional services aimed to equip our clients with high-quality research products and support critical decision-making.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11117498.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
2. Refractory Hematological Malignancies (MDS, AML) Market Emerging Therapeutics Analysis Available at ReportsnReports.com
3. Effects of alcohol on lymphoma, leukemia, and other types of hematological cancers
4. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
5. Clinical insight improves treatment with new lung cancer drug
6. Rapid Asthma Treatment in ER May Prevent Admission
7. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
8. Breast cancer patients suffer treatment-related side effects long after completing care
9. Mayo Clinic offers newly approved treatment for acid reflux disease
10. Mobile Stroke Units Might Trim Time to Treatment
11. Breast Cancer Treatment Side Effects May Last for Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... AL (PRWEB) , ... May 28, 2016 , ... May ... US Open Martial Arts Fighting Challenge with theme event of “K Warriors” on June ... Mobile, AL 36608. , The event is sponsored and hosted by Shaolin Institute ...
(Date:5/27/2016)... ... ... Two director-level employees of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) ... The award recognizes businesswomen who excel in their fields and who have made significant ... Long-Term Services and Supports) Program at Horizon NJ Health and Theresa Ponton, Director of ...
(Date:5/27/2016)... ... May 27, 2016 , ... An educational campaign aimed at ... stories, courtesy of awareness-driven celebrities and thought leaders. It also provides insight to ... industry leaders such as Bioness. , As patients feel increasingly concerned about ...
(Date:5/27/2016)... ... May 27, 2016 , ... Each ... studying complementary medicine. Allison Outerbridge is this year’s Life University winner ... 18 at the university’s Student Leadership Awards ceremony. , Outerbridge is approaching her ...
(Date:5/26/2016)... California (PRWEB) , ... May 26, 2016 , ... ... associated with discovery of thousands of defective respirators, according to court documents and ... the case of William and Becky Tyler v. American Optical Corporation, Case No. ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 2016 According to a new market ... - U.S. Industry Analysis, Size, Share, Growth, Trends, and Forecast ... U.S. was valued at US$ 5.89 Bn in 2014 and ... 2015 to 2023 to reach US$ 7.99 Bn in 2023. ... emerging needle free drug delivery devices and the market is ...
(Date:5/26/2016)... TARE (Transarterial Radio-embolization) Using ... and Overall Decreased Use of Hospital Resource ... specialist healthcare company, has today announced the publication ... of ISPOR (International Society for Pharmacoeconomics and Outcomes ... using yttrium-90 glass microspheres is associated with cost ...
(Date:5/26/2016)... Massachusetts , May 26, 2016 ... (NGS) has matured into an essential life science tool ... and development applications. BCC Research reveals in its new ... a second growth phase, one powered by a range ... fields.      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) ...
Breaking Medicine Technology: